RemeGen Co

RemeGen Co Short-term Debt

The Short-Term Debt of RemeGen Co (688331.SS) as of Oct 26, 2026 is 1.45 B CNY. In the previous year, Short-Term Debt was 1.43 B CNY — a change of 1.21% (higher).

Short-term Debt

1.45 BCNY

YoY

1.21%

Last updated:

Short-Term Debt of RemeGen Co is 2025 1.45 B CNY. Short-Term Debt of RemeGen Co was 2024 1.43 B CNY. It decreases by 1.21% higher compared to the previous year.

The RemeGen Co Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
859.42 M CNY
Jan 1, 2019
649.68 M CNY
Jan 1, 2020
151.11 M CNY
Jan 1, 2021
52.45 M CNY
Jan 1, 2022
60.15 M CNY
Jan 1, 2023
344.72 M CNY
Jan 1, 2024
1.43 B CNY
Jan 1, 2025
1.45 B CNY
The RemeGen Co Short-term Debt history
YEARShort-term DebtYoY
1.45 BCNY+1.21%
1.43 BCNY+315.57%
344.72 MCNY+473.06%
60.15 MCNY+14.68%
52.45 MCNY-65.29%
151.11 MCNY-76.74%
649.68 MCNY-24.40%
859.42 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Short-Term Debt of RemeGen Co is 1.45 B CNY in 2025.

Short-Term Debt of RemeGen Co changed from 1.43 B CNY to 1.45 B CNY, representing a 1.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — RemeGen Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — RemeGen Co